Phase II Study of High Dose Cyclophosphamide and Rituximab in Multiple Myeloma
- Determine the effect of rituximab and high-dose cyclophosphamide on the growth of
myeloma stem cells in patients with high-risk, refractory, or relapsed multiple
OUTLINE: Patients receive rituximab IV on days -10 and -7; once weekly for 4 weeks (after
completion of high-dose cyclophosphamide); and then once in months 3, 6, 9, and 12. Patients
also receive high-dose cyclophosphamide on days -3 to 0.
PROJECTED ACCRUAL: Not specified.
Masking: Open Label, Primary Purpose: Treatment
Event-free survival at 1 year
Carol A. Huff, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|